Acadia Pharmaceuticals Inc.
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER) sells ACAD shares
About this filing
Acadia Pharmaceuticals Inc. (ACAD) filed Form 4 (insider transaction) with the SEC on Aug 7, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Mark C. Schneyer · EVP, CHIEF FINANCIAL OFFICER
Rule 10b5-1 plan · adopted May 19, 2025
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +5,849 | $17.84 | $104,346.16 | 73,677 | Direct |
| Aug 5, 2026 | S · open-market saleFootnotes F2, F3 | −5,849 | $29.00 | $169,637.96 | 67,828 | Direct |
| Aug 6, 2026 | M · exercise or conversion of a derivative | +14,292 | $17.84 | $254,969.28 | 82,120 | Direct |
| Aug 6, 2026 | S · open-market saleFootnotes F2 | −5,000 | $29.00 | $145,000.00 | 77,120 | Direct |
| Aug 6, 2026 | S · open-market saleFootnotes F2 | −9,292 | $29.34 | $272,604.05 | 67,828 | Direct |
| Aug 5, 2026 | M · exercise or conversion of a derivativeStock Option (Right to Buy)Footnotes F4 | −5,849 | $0.00 | $0.00 | 74,715 | Direct |
| Aug 6, 2026 | M · exercise or conversion of a derivativeStock Option (Right to Buy)Footnotes F4 | −14,292 | $0.00 | $0.00 | 60,423 | Direct |
Footnotes
- F1 Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
- F2 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
- F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
More ACAD filings
- 4
Filed Oct 30, 2026
- 8-K
Filed Oct 23, 2026
- 8-K
Filed Sep 24, 2026
- 8-K
Filed Sep 11, 2026
- SC 13G
Filed Aug 7, 2026
- 144
Filed Aug 5, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.